Abstract
Mediation of antinociception via opioid receptors located in the periphery is a viable strategy to produce analgesia without the occurrence of side effects associated with stimulation of opioid receptors located in the central nervous system. Peripheral opioid receptors are particularly important in inflammatory pain states and in the responses to pruritogenic stimuli, and have been implicated in the transmission of visceral pain. Medicinal chemistry approaches to achieve peripheralization of opioid agonists have started with a centrally acting opioid agonist as a template, and introduced features of lipophilicity, hydrophilicity, or combined lipophilicity and hydrophilicity to achieve amphiphilicity. Quaternarization of centrally acting opioid agonists or identification of compounds that serve as substrates for the mdr transporter to achieve transport out of the brain has also been employed. The in vivo assays used to identify peripherally selective compounds have measured a variety of behavioral and pharmacokinetic endpoints, with varying degrees of predictability. This review focuses on a discussion of these methods, as well as a review of those compounds where sufficient data exist to support a claim of peripheralization in vivo.
Keywords: Opioid Agonists, lipophilicity, pharmacokinetic
Current Pharmaceutical Design
Title: Peripherally Restricted Opioid Agonists as Novel Analgesic Agents
Volume: 10 Issue: 7
Author(s): D. L. DeHaven-Hudkins and R. E. Dolle
Affiliation:
Keywords: Opioid Agonists, lipophilicity, pharmacokinetic
Abstract: Mediation of antinociception via opioid receptors located in the periphery is a viable strategy to produce analgesia without the occurrence of side effects associated with stimulation of opioid receptors located in the central nervous system. Peripheral opioid receptors are particularly important in inflammatory pain states and in the responses to pruritogenic stimuli, and have been implicated in the transmission of visceral pain. Medicinal chemistry approaches to achieve peripheralization of opioid agonists have started with a centrally acting opioid agonist as a template, and introduced features of lipophilicity, hydrophilicity, or combined lipophilicity and hydrophilicity to achieve amphiphilicity. Quaternarization of centrally acting opioid agonists or identification of compounds that serve as substrates for the mdr transporter to achieve transport out of the brain has also been employed. The in vivo assays used to identify peripherally selective compounds have measured a variety of behavioral and pharmacokinetic endpoints, with varying degrees of predictability. This review focuses on a discussion of these methods, as well as a review of those compounds where sufficient data exist to support a claim of peripheralization in vivo.
Export Options
About this article
Cite this article as:
DeHaven-Hudkins L. D. and Dolle E. R., Peripherally Restricted Opioid Agonists as Novel Analgesic Agents, Current Pharmaceutical Design 2004; 10 (7) . https://dx.doi.org/10.2174/1381612043453036
DOI https://dx.doi.org/10.2174/1381612043453036 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?
Current Vascular Pharmacology Surgical Treatment of the Sleep Apnea Syndrome in the Twenty-First Century
Current Respiratory Medicine Reviews Management of Type 2 Diabetes: More Evidence is Required to Address the Clinical and Contextual Facets
Current Diabetes Reviews Potential Application of Silver Nanoparticles in Medicine
Nanoscience & Nanotechnology-Asia Subject Index Volume 6
Mini-Reviews in Medicinal Chemistry Structure and Function of Poly(ADP-ribose) Polymerase-1: Role in Oxidative Stress-Related Pathologies
Current Vascular Pharmacology Overview: Translating Hsp90 Biology into Hsp90 Drugs
Current Cancer Drug Targets Retraction Notice: Microarray and Synchronization of Neuronal Differentiation with Pathway Changes in the Kyoto Encyclopedia of Genes and Genomes (KEGG) Databank in Nerve Growth Factor-Treated PC12 Cells
Current Neurovascular Research Role of Synovial Fibroblasts in Rheumatoid Arthritis
Current Pharmaceutical Design Chinese Herbal Medicine for the Treatment of Depression: Applications, Efficacies and Mechanisms
Current Pharmaceutical Design Olanzapine-Induced Reversible Pellagroid Skin Lesion
Current Drug Safety The Piccolo Intronic Single Nucleotide Polymorphism rs13438494 Regulates Dopamine and Serotonin Uptake and Shows Associations with Dependence-Like Behavior in Genomic Association Study
Current Molecular Medicine Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology Oxidation of Potassium Channels in Neurodegenerative Diseases: A Mini- Review
CNS & Neurological Disorders - Drug Targets Training Psychiatrists in Cognitive Behavioral Psychotherapy: Current Status and Horizons
Current Psychiatry Reviews A Sequential Ensemble Model for Communicable Disease Forecasting
Current Bioinformatics Psychopharmacology for Patients with Parkinson’s Disease and Deep Brain Stimulation: Lessons Learned in an Academic Center
Current Psychopharmacology Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis
Reviews on Recent Clinical Trials In Vitro Solubility Assays in Drug Discovery
Current Drug Metabolism Inhibition of Neurofibrillary Degeneration: A Promising Approach to Alzheimers Disease and Other Tauopathies
Current Drug Targets